Research programme: FOXA1 inhibitors - Curve Therapeutics
Latest Information Update: 28 Mar 2022
At a glance
- Originator Curve Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action FOXA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Breast cancer; Prostate cancer
Most Recent Events
- 25 Mar 2022 Research programme: FOXA1 inhibitors - Curve Therapeutics is available for licensing as of 25 Mar 2022. https://www.curvetx.com/partnering/
- 25 Mar 2022 Early research in Breast cancer in United Kingdom, prior to March 2022 (Curve Therapeutics pipeline, March 2022)
- 25 Mar 2022 Early research in Prostate cancer in United Kingdom, prior to March 2022 (Curve Therapeutics pipeline, March 2022)